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ABSTRACT 
Immune memory after vaccination is largely dependent on the combination of antibody 
production from long-lived plasma cells, and a supporting pool of antigen-primed memory B 
cells. It has been observed that individuals with certain immunosuppressive conditions or 
treatments have a weakened B cell memory, but the mechanisms behind remain elusive. The 
aim of this thesis was to evaluate B cell immunity in healthy children, and how HIV-1 
infection, antineoplastic therapy, and rheumatic disease and treatment can impact on various 
features of B cell memory induction and maintenance. 
In paper I, we explored the hyperactivation of B cells observed in patients carrying HIV-1 
infection, and showed that it can be partly induced by ligation of soluble cleaved CD27 to 
CD70 on the surface of memory B cells. In paper II, we aimed at comparing the 
establishment of serum antibody titers and memory B cells after vaccination against measles 
and rubella in healthy children. We found that the memory B cell pool remained stable also 
early after vaccination, whereas the corresponding serum IgG titers decayed with time. In 
contrast, both the serum IgG levels and frequency of blood memory B cells in healthy young 
adults appeared stable. This implied that the antibody production and memory B cell 
compartment are two separate entities with independent regulation, and that it takes longer 
time to establish a stable pool of circulating antibodies. How these two parts of B cell 
memory are affected by immunosuppressive disease and treatment was addressed in papers 
III and IV. In paper III, we used a rhesus macaque model for high-dose Doxorubicin 
treatment, and concluded that the established vaccine-induced memory B cell pool was 
depleted, contrary to long-lived plasma cells and the resulting serum IgG titers. These 
observations supported the finding of independent regulation of the two B cell memory 
compartments, and revealed different sensitivity to chemotherapy. The bone marrow plasma 
cell niche was additionally studied in an in vitro model for plasma cell – stromal cell cross 
talk, where we discovered that in vivo relevant concentrations of Doxorubicin could hamper 
the output of pivotal survival factors from stromal cells. In paper IV, we examined memory 
B cells and circulating IgG titers in children with rheumatic disease, treated with low-dose 
Methotrexate and TNF-α inhibition. We noted that serum IgG titers against tetanus were 
lower in rheumatic patients than in healthy controls, and that patients who had only received 
one measles vaccine dose had lower levels of measles-specific memory B cells. This stresses 
the importance for children with rheumatic disease and treatment to follow the full vaccine 
schedule. 
To summarize, this thesis has contributed to enhanced knowledge on how B cell memory is 
induced, preserved and at risk of disruption by common immune disorders and treatment. 
Hopefully, our findings can aid future improvement of functional vaccine regimes for 
immunocompromised children. 
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1 INTRODUCTION 
After vaccination, host protection against pathogens is dependent on one of the cardinal features 
of the adaptive immune system – immunological memory. One of the major players are B 
lymphocytes (B cells), eliciting a specific response by means of unique gene arrangement of 
each cell clone, producing exact matching of the B cell receptor to its target [1]. The aim of this 
thesis is to dissect how B cells contribute to life-long protection after vaccination, and how this 
can be hampered by immunosuppressive treatment. 
1.1 GENERAL FUNCTION AND DEVELOPMENT OF B CELLS  
B cells can act as modulatory cytokine-producing cells in many contexts, but their main effector 
function is to develop into plasma cells (PCs), and produce a soluble form of their receptor – 
antibodies (Abs). The following chapter will explore the characteristics of Abs, and how B cells 
mature and are maintained. 
1.1.1 B cell receptor functions  
The B cell receptor (BCR) is composed by a membrane bound immunoglobulin (Ig) molecule, 
which consists of repeated Ig protein motifs in two larger heavy chains and two smaller light 
chains, and the signaling chains Igα and Igβ [2, 3] (figure 1-1). The binding part of the Ig 
molecule, composed by both the heavy and light chains, recognizes a specific molecular 
signature, defined as an antigen (Ag). Since the specificity of each BCR is created in a 
stochastic manner, regulating functions are needed to enhance the response to pathogenic Ags, 
and inhibit actions towards self-Ags or non-pathogenic external Ags (for example food-related). 
These mechanisms are however not discussed within this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1.  Schematic image of the B cell receptor, where each segment represents an immunoglobulin (Ig) motif. 
The two joined longer chains are the heavy chains, where VH (red) is the variable region, and the brown segments 
the constant. The shorter chains are light chains, consisting of the yellow variable (VL), and the blue constant (CL) 
regions. The downstream signaling is initiated from the Ig-α – Ig-β complex.  
Image source: [3], printed with permission from Elsevier. 
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Table 1-1. Immunoglobulin isotypes existing as soluble antibodies, the most important factors leading to their 
production, and their most prominent functions. Phagocytosis is mediated through opsonization of antigens and 
subsequent binding to Fc receptors on innate phagocytic cells. References: [1] and [4]. 
As a mean of creating specificity for a large number of Ags, both light and heavy chains have 
regions of great variability between B cell clones (V regions), but also those more conserved (C 
regions) [1]. The conserved regions exist in different isotypes, named κ or λ for light chains, 
which are of unknown significance in humans. The heavy chain constant regions are named µ, 
δ, ε, α or γ, and determine the immunoglobulin isotype to IgM, IgD, IgE, IgA or IgG, 
respectively (including subtypes, not discussed here). Once activated, B cells can achieve the 
ability to produce soluble Igs, capable of different effector functions. Most of these are 
mediated through the Fc region of the heavy chain, which binds to various Fc receptors and 
elicit a variety of downstream actions (table 1-1) [1, 4]. The functions of IgA and IgE are 
beyond the scope of this work, which instead will focus on IgM and IgG. IgM is the first 
isotype produced by activated B cells, and has a limited binding strength (affinity). It is secreted 
as a pentamer, increasing the overall binding capacity (avidity), and mainly exerts its function 
through activation of the complement system. IgG is secreted as a monomer, is produced late in 
an Ag response and has higher affinity and capacity to neutralize pathogens, i.e. block them 
from further spread and pathogenic effects [5].  
1.1.2 Early B cell development 
B cells originate from hematopoietic precursor cells in the bone marrow (BM), where they 
receive signals from certain hematopoietic niches, composed of BM stromal cells expressing 
the ligand CXCL-12 (signaling through its receptor CXCR4) and IL-7 (signaling through the 
IL-7 receptor) [6]. B cells complete their maturation through several gene activation steps, of 
Isotype 
Main switch 
signal  
Main source of 
switch signal 
Main effector 
functions 
IgM 
Non-switched 
heavy chain 
- Complement activation 
    
IgA TGF-β 
Epithelial and 
dendritic cells in 
mucosal tissue 
Activation of innate 
cells (e.g. phagocytosis 
and cytotoxic effects) 
    
IgE IL-4 
Th2 cells  
(also TFH2 cells) 
Mast cell degranulation 
    
IgG IFN-γ 
Th1 cells  
(also TFH1 cells) 
Phagocytosis, 
complement activation, 
neutralization 
Th = Helper T cell, TFH = Follicular helper T cell 
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which some of the most crucial lead to assembly of the BCR [7]. The specificity of every B cell 
clone is enabled through rearrangement of variable (V), diversity (D) and joining (J) segments 
of the germline DNA to an enormous diversity of possible heavy chains, and the similar 
rearrangement of V and J segments of the light chains [7, 8]. The constant regions initially 
contain information to code for more than one heavy or light chain, but become fixed 
throughout the maturation and differentiation process (discussed below). The process of gene 
recombination is orchestrated by the proteins recombination-activating gene 1 and 2 (Rag-1 and 
Rag-2), that together form the V(D)J recombinase complex [1]. 
The first recombination of Ig genes occurs in the precursor called pro-B cell, committed to the 
B cell lineage based on its expression of the B cell-restricted molecules CD19 and CD10 [1]. 
The production of the V(D)J recombinase complex induces assembly of the µ type of Ig heavy 
chain, which together with Igα, Igβ, and proteins similar to light chains (surrogate light chains), 
composes the pre-BCR and defines the pre-B cell stage [6]. Ag-independent pre-BCR signaling 
leads to subsequent formation of light chains, that together with the µ heavy chain constitutes a 
BCR of IgM type, which defines the immature B cell stage. Pre-BCR and BCR signaling are 
the main conveyors of survival and proliferation signals to B cells, which are mediated through 
Bruton’s Tyrosine Kinase (BTK). As only self-Ags are available in the BM, too high BCR 
binding will result in re-editing through activation of Rag genes, or to apoptosis [1]. After 
leaving the BM, the immature B cells enter the process of final maturation, in which they are 
classified into the transitional stages T1, T2 and T3, based on phenotypic changes. This 
probably occurs in the peripheral blood in humans [9], and includes increase of CD21 
expression, loss of CD10 and CD5, and alternative splicing of the Ig heavy chain, which leads 
to dual expression of IgD and IgM [1, 10-12]. 
After maturation, a subgroup of B cells populates the marginal zone (MZ) of the spleen and 
subcapsular areas of lymph nodes, and lowers its IgD expression. These are MZ B cells, and are 
semi-equivalent to innate cells due to their ability to respond with early and less specific Ab 
production [13]. The majority of mature B cells will however circulate through the blood stream 
and secondary lymphoid organs (SLOs), and are called follicular B cells or recirculating B cells 
[1, 7]. The mechanism for commitment to either lineage is not fully elucidated, but signaling 
through toll-like receptors (TLRs) and lower BCR affinity probably favors MZ B cell 
development [13]. B-1 cells are an additional type of B cell with similar function as MZ B cells, 
but developed through a different pathway in fetal liver, and located in the peritoneum and 
mucosal sites. Both B-1 and MZ B cells were earlier considered a murine feature, but there is 
now convincing evidence for their existence in humans [1, 13-16].  
1.1.3 Homeostasis of mature B cells 
The mature naïve B cells are dependent on survival signals generated by Ag binding of the 
BCR, and of ligation of the Tumor Necrosis Factor (TNF) family of receptors by B cell 
activator of the TNF-α family (BAFF) [7]. BAFF is produced by many cell types, most 
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importantly from myeloid cells such as monocytes, and can bind to three receptors. The most 
widely expressed, BAFFr, appear first on immature B cells in the BM, and are expressed on all 
B cells except for PCs [17]. The second receptor, transmembrane activator, calcium modulator, 
and cyclophilin ligand interactor (TACI), is found on all peripheral B cells, most notably on 
MZ B cells. The third receptor, B cell maturation antigen (BCMA), is upregulated at the later 
stages of B cell differentiation, most pronounced on PCs [18]. The latter two receptors can also 
be ligated by the homologous ligand a proliferation-inducing ligand (APRIL). Stimulation of 
these receptors is crucial for providing survival signals to mature B cells, and aid throughout 
further differentiation [7].  
1.2 B CELL ACTIVATION AND ANTIBODY PRODUCTION 
B cell activation is initiated through a combination of Ag encounter and auxiliary signals, 
leading to a cascade of events with the final goal of PC differentiation and Ab production. Later 
in the response, PCs produce Abs with enhanced affinity through the process of affinity 
maturation, and a variety of Ab isotypes are secreted after induction of class switch. The B cell 
response to non-pathogenic Ags is beyond the scope of this thesis, and this chapter will focus on 
protection from pathogens. 
1.2.1 Ag encounter 
Invading pathogens will encounter MZ, B-1 and follicular B cells on their respective locations 
in SLOs or peritoneum, where the naïve (Ag-inexperienced) B cells bind to their specific Ag. 
To become activated, several BCRs need to be co-localized in a process that is not completely 
understood, but is thought to involve either cross-linking of receptor monomers or dissociation 
of oligomers [2, 19]. Effective co-localization of BCRs is enhanced if the Ag has multiple 
binding sites (epitopes), hence classified as multivalent, compared to monovalent Ags with only 
one single epitope [20]. In addition, the B cells need secondary signals, traditionally classified 
into thymus independent (TI) and thymus dependent (TD), based on T cell involvement. Recent 
studies have provided evidence that TI Ag responses are more complex than previously 
assumed, involving activation signals from both innate-like lymphoid cells such as iNKT cells, 
and innate cells such as monocytes and basophils [21]. Numerous studies have also shown that 
the classification of Ag responses is more faceted than previously known, leading some 
researchers to suggest a shift of the TI versus TD paradigm [22]. However, the B cell response 
to Ag encounter will here be presented using the established nomenclature. 
1.2.2 TI Ag responses 
Non-protein Ags cannot be presented to T cells, and are therefore classified as TI Ags. MZ and 
B-1 B cells are the first to encounter incoming Ags, due to their location, and are the foremost 
executors of the TI B cell response [13, 22]. They receive secondary signals through the B cell 
co-receptor complex, constituted by complement receptor 2 (CD21), CD19 and CD81 [1, 23]. 
This enhances the signal evoked by the Igα and Igβ parts of the BCR, together leading to 
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phosphorylation of the Src family of kinases [1]. Ligation of TLR5, TLR7 and TLR9, 
recognizing pathogen-associated molecular patterns (PAMPs), can further augment the signal 
strength [23]. Recently, it has been shown that BCR signals are dependent on CD19, also 
without the co-receptor complex, to induce the clusters of receptors that are needed for signal 
transmission [23]. TI responses are only possible towards Ags that yield adequate TLR signals 
(TI-I Ags, for example viral RNA) or are multivalent, leading to ample BCR signaling (TI-II 
Ags, for example bacterial polysaccharides). Recently, a TI-III type of response, that is elicited 
towards non-protein Ags with the help of myeloid innate cells, has also been discovered [22].  
Following downstream signaling of a TI response, the B cells activate the transcription factors 
Blimp-1 and IRF4, which in turn induces expression of XBP-1, important for handling of 
increased protein production. This initiates a differentiation process that also includes cell size 
increase and alternative processing of µ heavy chain RNA, leading to soluble IgM production 
[1]. The finally matured cells are called short-lived PCs (SLPCs), and produce Abs for 
approximately 3 days before cell death [24]. New SLPCs are produced as long as the Ab 
response continues, but there is also some evidence of memory induction (see chapter 1.3.3). 
Even though some of the cardinal features of the TI response are low affinity Abs and limitation 
to IgM production, it is becoming more evident that affinity maturation and class switch can be 
induced also without T cell help, preferentially in TI-III responses [13, 15, 22].  
1.2.3 TD Ag responses 
TD Ag responses are mainly attributed to follicular B cells, in a reaction that occurs in the B 
cell areas, follicles, of SLOs. As the B cells enter SLOs through blood vessels, they migrate 
towards the follicle due to a gradient of stromal cell-secreted CXCL-13, binding to CXCR5 on 
their surface [1]. Residing follicular dendritic cells (FDCs) capture and present incoming 
protein Ags to B cells, but do not provide sufficient secondary signals for full activation. A 
successful TD response is elicited only if the B cell engulfs the Ag for presentation to T cells, 
albeit TLR and CD21 signaling do have an augmenting role [25, 26]. In addition, the strength of 
the TD response is enhanced if the protein Ag is multivalent (see chapter 1.4.2)  
T cell encounter is facilitated through expression of CCR7, which directs the B cells towards 
the edge of the follicle by the T cell zone chemokines CCL19 and CCL21. T cells, that are 
activated by the same Ag (defined as cognate T cells) and express the chemokine CXCR5, in 
turn migrate towards the follicle [1]. B cells present the Ag via MHC II molecules, binding to 
the T cell receptor (TCR), but the cross talk also involves a variety of co-stimulatory molecules, 
which are upregulated upon activation. Some of the most important T cell-expressed molecules 
are CD28, CD40 and inducible T cell co-stimulator (ICOS), binding in respective order to 
CD86, CD40-ligand and ICOS-ligand on B cells. T cells also secrete soluble IL-21, binding to 
the IL-21 receptor [27, 28].  
 12 
The B and T cell interaction, augmented by signals from FDCs, leads to differentiation of T 
cells into follicular helper T cells (TFH cells) through expression of the transcription factor Bcl-6 
[29]. TFH cells in turn drive the further B cell differentiation, either to become extrafollicular 
SLPCs, by expression of Blimp-1, or to proceed into a germinal center (GC). The latter requires 
a halt in the PC differentiation process, facilitated by B cell expression of Bcl-6, which inhibits 
Blimp-1. The mechanisms for up-regulation of Bcl-6 are not known, but it is thought to be 
dependent on a competition between B cells with high and low affinity BCRs [27, 28, 30, 31]. 
1.2.4 The GC reaction (figure 1-2) 
The GC reaction is initiated as the B and T cells migrate back to the B cell follicle, now defined 
as secondary follicle. It is most commonly formed 4-7 days after initiation of the response, and 
can persist for weeks or months depending on the Ag [1, 32, 33]. Bcl-6 expression facilitates 
continuous cell cycle entry, leading to rapid B cell proliferation. This occurs within the dark 
zone of the GC, where abundant levels of the ligand CXCL-12 maintain B cells that express 
CXCR4 [34]. Cells expressing higher levels of CXCR5 migrate towards CXCL-13 in the light 
zone, where FDCs present the Ag and induce BCR signaling, and TFH cells provide auxiliary 
signals [30]. B cells with low affinity BCRs and low expression of co-stimulatory receptors will 
eventually die by apoptosis due to lack of survival signals [27, 28], and lack of prevention from 
apoptosis induced by the death receptor Fas [35]. Also, signals from the receptor PD-1 on TFH 
cells, binding to the ligands PD-L1 and PD-L2 on B cells, stimulate survival and maturation in 
the GC [36]. Recirculation between the light and dark zone enables an iterative process of 
selection, leading to gradually increased affinity of the BCRs (affinity maturation) for each 
round of mutations that occurs [27, 28]. This is further enhanced by induction of somatic 
hypermutation (discussed below), and a gradual decrease of Ag availability, strengthening the 
selection pressure on binding affinity.  
B cells within the GC are sometimes defined as either centroblasts (proliferating cells in the 
dark zone), or more mature centrocytes (undergoing selection process in the light zone). 
However, the growing understanding of the dynamic process of cells moving between the 
zones, and the lack of phenotypic markers for either cell type, has led to a questioning of this 
terminology [28].  
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Figure 1-2. Illustrated model of the germinal center (GC) reaction. B cells enter the dark zone, based on 
competition for T cell interaction, where they proliferate and mutate at an extremely high rate. The cycling between 
the dark and light zones is guided through concentrations of the cytokines CXCL-12 and CXCL-13, and their 
ligands CXCR4 and CXCR5. Survival signals are provided in the light zone both from follicular dendritic cells 
(FDCs) and follicular helper T cells (TFH), fine-tuning the B cell selection based on both B cell receptor affinity and 
access to T cell help. Cells that are not killed by apoptosis exit the GC as memory B cells, or as plasma blasts, later 
maturing to plasma cells. 
Image source: [28], printed with permission from Annual Reviews. 
 
1.2.4.1 Somatic hypermutation 
Somatic hypermutation is defined as the extreme rate of mutations induced in proliferating B 
cells in the dark zone of the GC. It is initiated by the enzyme activation-induced deaminase 
(AID), triggered by T cell signals, most importantly CD40 [1]. AID targets recombined V 
regions in the Ig coding sequence, leading to deamination of deoxycytidine into deoxyuridine 
and a C-G mismatch [37]. Depending on the type of DNA repairing enzyme, the DNA damage 
can induce both point mutations into T-A base pairs, or extended mutations due to error-prone 
repair [37]. This series of events utterly induces mutations at a rate up to 1000 times higher than 
in normally replicating cells [1], providing a higher probability of generating clones with a new 
affinity of the BCR. The rate of somatic hypermutation in extrafollicular sites is very low, but 
has been shown to increase in certain autoimmune contexts [38].     
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1.2.4.2 Class switch recombination  
Exchange of the Ig µ and δ heavy chains to α, ε or γ defines class switch from the IgM isotype, 
to IgA, IgE or IgG. Naïve B cells have constant DNA regions coding for each of the isotypes, 
and cytokines from helper T cells and other sources (table 1-1) induce transcription of one of 
the isotype-specific DNA loci, producing a germline transcript. This acts in an unknown way to 
facilitate the next rearrangement [39], in which AID targets specific switch regions adjoining 
both the µ and germline loci. Due to numerous tandem repeats of GC-sequences, these regions 
are particularly vulnerable to the deaminase activity by AID, and subsequent action by the 
enzyme uracil DNA glycosylase (UNG) leads to double strand breaks in the DNA code [1, 39]. 
The two switch regions are then joined together, deleting the intervening DNA and fixing the B 
cell isotype to a new heavy chain. Appearance of switched B cells before establishment of GCs 
[40], and the notion that prevention of GC formation did not eradicate switched cells [32], led to 
the conclusion that class switch is induced upon the first extrafollicular cognate contact between 
B and T cells, before creation of a secondary follicle. However, class switch still occurs 
throughout the GC reaction [24]. 
1.3 B CELL MEMORY 
One of the major outcomes of an immune response is the generation of immunological memory, 
conveyed by both B and T cell specific mechanisms [41]. The details of the T cell memory 
compartment is however beyond the scope of this thesis, which will focus on the different 
layers of B cell memory.  
1.3.1 Two lines of B cell memory  
The first line defense of B cell memory is constituted by constantly circulating Abs against 
previously encountered Ags, able to elicit effector functions (table 1-1) at an early stage of 
pathogen invasion [42]. If the neutralizing effect is insufficient to protect the host, there is 
initiation of the second line defense, consisting of dwelling memory B cells (MBCs) that 
rapidly become activated and differentiate into Ab-producing SLPCs. The half-life of an IgG 
molecule is estimated to be 21-28 days and for long, the origin of circulating Abs against Ags 
that were encountered many years ago was an unresolved issue in immunology [1]. However, 
recent advances have confirmed the existence of long-lived PCs (LLPCs) located in the BM and 
mucosal sites, constantly secreting Abs [43]. Both LLPCs and MBCs demonstrate an 
extraordinary longevity independent of recurrent Ag stimulation, proven by the fact that both 
Abs and MBCs can be found in individuals vaccinated against smallpox more than 50 years 
ago, despite the impossibility of Ag re-encounter [44]. Previous hypotheses suggesting 
preserved Ags in various reservoirs have now been abandoned, due to accumulating evidence of 
Ag-independent Ab preservation [42, 45].  
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1.3.2 Generation of LLPCs and MBCs against TD Ags 
The exit of B cells from the GC reaction gives rise to both MBCs and LLPCs, but the signals 
regulating which fate remain elusive [27]. The affinity to the Ag is proposed as the main 
determinant, since the MBC compartment contains cells with both high- and low-affinity BCRs, 
whereas the PCs produce uniformly high affinity Abs [46]. Selection of high-affinity GC B 
cells with PC potential probably occurs early in the GC reaction, given the early expression of 
Blimp-1 (see chapter 1.2.2) in some B cells [28, 46]. The mechanism behind this selection 
remains to be shown, but it is clear that increased T cell interaction through CD40 and MHC II-
TCR ligation favors the PC pathway [28, 32]. Expression of Blimp-1 leads to formation of 
plasma blasts, which exit from the GC most probably due to T cell produced IL-21 [28, 30]. 
They subsequently migrate to SLOs and BM to complete their final maturation into SLPCs or 
LLPCs (see chapter 1.3.8). 
In contrast to PCs, MBCs seem to be formed throughout the entire GC reaction, and benefit 
from prolonging GC sustention but less from specific T cell help [28, 30]. They continue to 
express Bcl-6, keeping them within the GC reaction, until they utterly leave the GC by largely 
unknown mechanisms. Possibly, IL-21 is involved also in MBC exit [1, 28]. The fact that the 
first MBCs appear in the periphery before LLPCs has also led to an alternative hypothesis of a 
temporal division, suggesting that MBCs are formed early, and LLPCs late, in the GC reaction. 
The peak LLPC production occurs 4-5 weeks after Ag encounter [47]. 
There is increasing evidence that MBCs and LLPCs form also in extrafollicular sites, albeit with 
a lower selection pressure and hence having lower affinity [32, 48]. This can possibly explain 
existing TD Ag-specific MBCs with limited or no hypermutation in their V regions [32], and 
the presence of an IgM-expressing subgroup of MBCs [49]. 
1.3.3 TI B cell memory 
Although numerous observations in both mice and humans stress the importance of T cell help 
for a robust B cell memory initiation, existence of a TI B cell memory is virtually confirmed, 
and might be an additional source of IgM+ MBCs. Several experimental models have shown 
mounting of LLPCs and MBCs against TI-I and TI-II Ags [22, 50] in the absence of T cell help. 
Though, the most intriguing proof of TI memory in humans is the existence of somatically 
mutated IgM+ MBCs in patients with genetic defects in CD40-Ligand, ICOS or the adaptor 
molecule SAP, all three independently leading to absent GCs [51]. The mechanisms behind TI 
B cell memory need more exploration, but probably involve activation of MZ and B-1 B cells, 
and help of other innate-like lymphoid cells [22]. The resulting MBCs are sometimes classified 
as innate-like MBCs [52]. 
1.3.4 Heterogeneity of the MBC compartment (table 1-2) 
The pre-conceived notion that MBCs are isotype-switched and generated from GC responses, 
led immunologists to define the B cell developmental stages through the expression of IgD (lost 
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upon switching) and the signaling molecule CD38 (generated upon activation), to the Bm1-
Bm5 stages [53]. This model postulates loss of IgD to define all memory stages, and can thus 
not be used to identify non-switched MBCs. The discovery by Klein et al that the TNF receptor 
family protein CD27 is expressed on B cells that have undergone V recombination [54], 
resulted in a new classification based on IgD and CD27 expression, defining MBCs as CD27+, 
divided into an IgD+ non-switched and an IgD- switched population [53]. It was however clear 
that a subpopulation of B cells lacked both markers, thus not falling into the definition of either 
naïve or MBCs, and defined as “double negative” B cells. These were shown to have memory 
properties, and to be increased in patients with the autoimmune disorder Systemic Lupus 
Erythematous (SLE), especially in active disease [55, 56]. Characterizing this population 
further, Jacobi et al showed that a subpopulation of these cells displayed an activated phenotype 
that correlated with disease flares, and could be identified using the “death receptor” Fas 
(CD95) [57].  
Another important classification of heterogeneous MBC subpopulations has been done in 
individuals infected with Human Immunodeficiency Virus 1 (HIV-1), in whom Moir and 
colleagues found that CD27+ MBCs down-regulated CD21 upon activation and differentiation 
into Ab-producing PCs, and suggested the name “activated MBCs” for the CD27+ CD21low B 
cell phenotype [58, 59]. Meanwhile, parallel investigation of human tonsils revealed CD27- B 
cells, showing memory properties, that lacked expression of CD21, and expressed the putative 
inhibitory receptor Fc-­‐‑receptor-­‐‑like 4 (FcRL4) [60]. FcRL4 was also confirmed on circulating 
CD27- CD21- MBCs in HIV-1 infected individuals, and this subpopulation was consequently 
named “tissue-like MBCs” [61]. They displayed an unresponsive phenotype, expressing 
inhibitory receptors such as CD22 and LAIR-1, and were suggested to be a result of immune 
exhaustion [62], in contrast to the activated CD27- cells in SLE (lacking expression of FcRL4) 
[55].  CD21- CD27- MBCs are likewise enriched during primary CMV infection [63] and in 
individuals chronically infected with hepatitis [64], and malaria [65], but have also been found 
in patients with Sjögren’s Syndrome [66]. Weiss et al suggested the name “atypical” instead of 
“tissue-like” for the CD21- CD27- phenotype in malaria, given the fact that their function is less 
explored and not verified as exhausted, and this terminology is used in parallel [65]. 
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IgD/CD38 MBC classification 
 
CD27/IgD MBC classification 
 
CD27/CD21 MBC classification 
  
 
Function  
Transi-
tional B 
cells 
 
Bm1: 
virgin 
naïve 
Bm2: 
activated 
naïve 
Bm3-
Bm4: GC 
cells 
Bm5: 
memory 
Plasma 
blasts 
 
Mature 
naïve 
Non-
switched 
memory 
Switched 
memory 
Double 
negative 
Plasma 
blasts 
 
Mature 
naïve 
Resting 
memory 
Activated 
memory 
Tissue-
like/atypical 
memory 
 
Long-lived 
plasma 
cells 
CD10 
Metallo-
proteinase with 
unknown 
significance 
 
+* 
 
- - - - - 
 
- - - - - 
 
- - - - 
 
- 
CD19 
Part of BCR co-
receptor complex 
 
+ 
 
+ + + + + 
 
+ + + + + 
 
+ + + + 
 
+/- 
CD21 
Complement 
receptor 2, 
ligated by Cd3 
 
+** 
 
ND ND ND ND ND 
 
ND ND ND ND ND 
 
+ + -/low - 
  
CD27 
Induces Ab 
secretion and 
differentiation 
 
- 
 
ND ND ND ND ND 
 
- + + - ++ 
 
- + + - 
 
++ 
IgD 
Early BCR, not 
secreted 
 
- ** 
 
+ + - - - 
 
+ + - - - 
 
+ +/- +/- +/- 
 
- 
IgM 
Early BCR, 
secreted as Ab 
 
+ 
 
+ + +/- +/- +/- 
 
+ + - +/- - 
 
+ +/- +/- +/- 
 
+/- 
CD38 
Proliferation or 
inhibition 
depending on 
maturation stage 
 
+ 
 
- + + -/low ++ 
 
- +/- +/- +/- ++ 
 
- -/low ND + 
 
++ 
CD138 
Adhesion 
molecule 
 
- 
 
- - - - ND 
 
- - - - +/- 
 
- - - - 
 
+/- 
                       
ND = not determined, BCR = B cell receptor, MBC = memory B cell, Ab = Antibody; * decreasing with maturation, ** increasing with maturation 
 
 
Table 1-2. Selected surface protein expression on the most important B cell populations. Three modes of memory B cell (MBC) classification is presented: the Bm1-5 classification, 
based on expression of IgD and CD38, the CD27/IgD classification, and finally the classification suggested by Moir et al, based on expression of CD27 and CD21. References: [53, 62, 
67, 68]
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1.3.4.1 The role of CD27 on MBCs 
The ligand of CD27 is the TNF-like molecule CD70, which is transiently expressed on 
activated B, T and dendritic cells, and act co-stimulatory on CD27-expressing T and B cells. 
CD70 can also induce downstream activation on its host cell upon ligation [69]. Even before 
the confirmation of CD27 as a marker for V recombination, functional studies revealed that 
CD27+ B cells were superior in producing IgG, an effect that was more pronounced after 
addition of CD70 [70]. Further in vitro studies confirmed that soluble CD70, with addition of 
the cytokines IL-2 and IL-10, promoted differentiation of CD27+ MBCs into Ab-secreting 
cells [71]. Coherent with these findings, tissue-like MBCs lacking CD27 were proven to be 
less proliferative and prone to secrete Abs [61]. However, given the prominent expression of 
inhibitory receptors on these cells, and their parallel loss of co-stimulatory CD21, the relative 
contribution of CD27 down-regulation to their impaired response is yet to be determined.  
An alternative way for B cells to loose CD27 surface expression is through proteolytic 
cleavage of the putative ligand-binding domain, producing the soluble form (sCD27). This 
molecule is increased in serum of HIV-1 infected individuals, as well as in and other immune 
disorders and malignancies [72, 73], and its role has been addressed in a number of studies. B 
cells from patients with the B cell malignancy Waldenström macroglobulinemia upregulated 
CD40-ligand upon sCD27 ligation to CD70 [74], and experimental ligation of CD70 on the 
surface of activated B cells has been shown to induce proliferation in mice [75]. Somewhat 
contradictory, another outcome from the murine model was inhibited PC differentiation and 
IgG production [75], suggesting a dual role for the CD27-CD70 cross talk, possibly different 
in mice compared to humans, and/or in normal compared to pathological conditions.  
1.3.5 The pediatric MBC compartment 
The majority of knowledge about B cell development and function is derived from studies in 
adult murine and human models, and existing differences in children is insufficiently 
elucidated. In addition to B cell function, changes in the T cell compartment and innate 
immune system contribute to changes in the overall B cell response. A full review of the 
development of the immune system in the growing child is beyond the scope of this thesis, 
but some points regarding the MBC compartment need to be addressed.  
Firstly, the relative proportion B cells of the lymphocyte population is approximately 20 % at 
birth, and then successively declining until it reaches the adult level of 10 % at the age of 16 
[76, 77]. Secondly, Ag exposure is as a rule initiated after birth. Thus, the majority of fetal B 
cells are of naïve type, and the MBC compartment is gradually expanded with increasing age 
[77, 78]. This also accounts for class switched cells, as demonstrated by the fact that IgG+ B 
cells are 70% and IgA+ 30 % of adult levels at the age of 1 year [78]. Furthermore, the 
proportion of transitional B cells out of the total B cell population is notably increased in 
young children (>10 % and up to 30 % in one study), reaching adult levels (< 5 %) after the 
age of 16 [76, 77]. In addition to quantitative changes, the TI Ag response is suboptimal in 
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children below 2 years of age, probably due to reduced expression of CD21 and incomplete 
maturation of the MZ of the spleen [78]. 
1.3.6 Survival of MBCs 
Several mouse and human studies have aimed to localize a spatial compartment for 
maintenance of MBCs, but this remains elusive. Splenectomized humans have reduced, but 
not diminished, MBCs, suggesting redundant sites of maintenance [45]. MBCs have been 
found outside follicles, such as in the MZ or adjacent to GCs in the spleen [79], and in 
mucosal epithelium in human tonsils [80]. The number of MBCs that is found in peripheral 
blood is probably 100 times less than in the spleen [80]. The current consensus is that MBCs 
are preserved mainly in multiple SLOs, and that a proportion recirculates in the periphery 
[32]. 
In contrast to naïve B cells, MBCs are independent on both BCR and BAFF/APRIL 
stimulation [18, 45]. They seem to have a faster proliferation rate than naïve B cells [81], thus 
probably maintained through continuous turnover rather than being long-lived. Despite this, 
they do not express Bcl-6, known as an important inducer of proliferation [80]. The major 
MBC survival signal identified is the anti-apoptotic molecule Bcl-2 [32], and also telomere 
elongation is of pivotal importance [45]. The details behind their maintenance is however to a 
large extent unknown.  
1.3.7 Re-activation of MBCs 
To produce specific Abs, MBCs have to receive specific BCR stimulation and go through a 
new activation process, involving up-regulation of Blimp-1 and differentiation to SLPCs 
[43]. The reasons for their efficient and swift response compared to naïve B cells are several. 
Primarily, the clonal expansion during the GC response generate a repertoire of MBCs 
specific for previously encountered Ags, in contrast to the stochastic production of naïve B 
cell receptors. The strategic location of MBCs outside follicles promotes fast encounter with 
incoming Ags, and efficient downstream signals are yielded by affinity matured BCRs. 
Furthermore, they have a high expression of TLRs and CD21, enabling effective activation, 
and already express important T cell activation receptors, such as CD86 and MHC, that 
prepare them for a rapid response upon T cell help [80]. Ag-primed TFH of memory type are 
feasible candidates for the T cell part of the recall response [27]. There is also recent evidence 
for secondary GC formation by a subgroup of IgM+ MBCs, leading to a second layer of GC 
response upon re-challenge with an Ag [33]. This might be one explanation for the increased 
formation of LLPCs that is noted after a booster immunization [27]. 
1.3.8 Survival of LLPCs 
The most intriguing proof that MBCs are dispensable for continuous Ab secretion has been 
studies in both mice and humans showing that depletion of all B cells before the PC 
differentiation stage did not affect previously acquired Ab titers [82]. In addition, there have 
been numerous observations of vaccine-specific PCs in human BM [83]. After differentiation 
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and exit from the GC, Ab-secreting plasma blasts upregulate the surface expression of 
CXCR4 and migrate towards CXCL-12 secreting cells in BM and extrafollicular sites of 
SLOs [83-85]. Since CXCL-12 also is abundant in the GC, there are probably additional 
migratory factors involved [85]. As the plasma blasts have reached the final maturation sites, 
they stop proliferating and acquire the cell adhesion proteoglycan CD138, reaching the 
mature PC stage [86, 87]. PCs in SLOs are short-lived, demonstrated by high apoptosis rate, 
but there is some evidence of prolonged survival of PCs also in the spleen [88] and 
inflammatory sites in SLE [89]. Furthermore, long-lived IgA secreting PCs are partly 
maintained in mucosal areas [90, 91]. However, the uttermost niche for PC survival in 
humans is the BM [83-85], recently demonstrated in a study in which vaccine-induced serum 
Abs strongly correlated to corresponding BM-resident PCs (BMPCs) [92]. 
1.3.9 PC survival factors and composition of the BM niche 
PCs generally loose expression of the BCR, with the exception of IgA-switched PCs, and are 
thus independent of Ag for survival signals [93]. Instead, they are dependent on a variety of 
nursing cells that provide necessary membrane-bound and soluble survival factors. The most 
pivotal intracellular signaling molecule identified for PC survival is Mcl-1, induced by 
binding to the BCMA receptor (see chapter 1.1.3) [32, 84, 85]. Murine studies have 
concluded that the major BCMA ligand in the BM is APRIL, but this remains to be shown in 
humans [94]. Other PC receptor-ligand pairs of importance for survival are IL-6R-IL6, 
CD28-CD80/CD86, and CXCL-12-CXCR4, as well as direct contact to the adhesion 
molecule VCAM-1, bound to VLA-4 on PCs [84, 85]. Binding of hyaluronic acid from 
extracellular matrix to CD44 gives a pronounced survival potential in vitro [95], but this 
finding is yet to be confirmed in vivo [85].The necessary signals are provided within the 
BMPC survival niche (figure 1-3), recently characterized in more detail as a combination of 
resting stromal cells, and proliferating hematopoietic cells [96]. The stromal cells in the BM 
constitutes < 1 % of the total BM cellularity, and include a variety of terminally differentiated 
mesenchymal stem cells of reticular character. It has been estimated that approximately 17 % 
of all BM stromal cells are specialized for PC survival, defined by the fact that they do not 
produce the B cell maturation cytokine IL-7, but instead express high levels of CXCL-12 and 
VCAM-1 [83]. These stromal cells are called CXCL-12-abundant reticular cells (CAR cells) 
[97]. The other mentioned survival factors are provided by the hematopoietic part of the 
niche. CD80 and CD86 are common activation ligands that are expressed on dendritic cells, 
including in the BM [98]. The majority of APRIL and IL-6 is estimated to be produced by 
megakaryocytes [99] and cells of myeloid origin, of which half are eosinophils in different 
developmental stages [97, 100]. Also basophils have been connected to increased BMPC 
survival by means of IL-6 production [101]. One model has suggested that the major role for 
CAR cells is to provide the overall structure that brings the essential nursing cells together 
[97], but this is not yet confirmed. Further research in both animal models and human 
samples is needed to fully understand the traits of the BMPC niche.  
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Figure 1-3. One model suggested by Belnoue et al, summarizing the current understanding of the bone marrow 
niche for long-lived plasma cells. Static CXCL-12-abundant reticular cells (CAR cells) of mesenchymal origin 
create the reticular network behind the niche structure, and provide CXCL-12. The proliferating hematopoietic 
cells within the niche secrete the additional soluble survival factors APRIL and IL-6. Not shown in the figure are 
the activation ligands CD80 and CD86, provided by dendritic cells, and the adhesion molecule VCAM-1, 
provided by CAR cells. MGK = megakaryocytes. Image source: [97], printed with permission from the Journal 
of Immunology. Copyright 2012. The American Association of Immunologists, Inc. 
1.4 VACCINES  
The first published description of how deliberate inoculation of an Ag induced immunity 
against a disease came out in 1798, when Edward Jenner described how insertion of pustule 
fluid with the virus Variolae Vaccinae (Cow Pox) protected from Small Pox inoculation 
[102]. Since then, we have begun to understand the mechanisms behind the generation of 
protective long-term immunity, which has enabled the design of new and more efficient 
vaccines against a variety of pathogens. Evaluation of vaccine efficacy has revealed that both 
T and B cell immunity is crucial for vaccine function [103]. However this thesis will focus on 
the B cell part of vaccine-induced memory. 
1.4.1 Vaccine design 
The three most crucial steps of inducing a long-term B cell memory are to (i) present an 
exposed epitope on the pathogen surface, (ii) to stimulate the innate immune system in order 
to provide secondary activation signals to B and T cells, and (iii) to evoke a TD immune 
response, which has a higher potential than TI responses to generate MBCs and LLPCs [1]. 
There are various strategies to reach the three goals, of which the first was attenuating or 
killing whole pathogens, used as soon as cultivation of viruses in vitro became possible [103]. 
Attenuated live vaccines containing replicating virus or bacteria are the most effective 
imitators of true infection, thereby powerfully inducing the mentioned mechanisms. In 
contrast, inactivated or killed pathogens fail to yield innate responses, and a general immune 
stimulus (adjuvant) is included in these vaccines [20, 104]. Various artificial adjuvants can be 
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used, such as aluminum salt that releases danger signals from host cells, but also TLR-
stimulating viral proteins and bacterial subunits have been approved [104]. The discovery that 
the protective Abs often are directed towards selected strategic sites led to the idea of using 
subunits of pathogens as epitopes, which has been a successful method when using protein 
Ags. However, the bacterial polysaccharide capsule cannot be presented to T cells, and only 
induces a TI response. This lead to the development of conjugate vaccines consisting of 
polysaccharide epitopes with an attached immunogenic peptide. The BCR reacts against the 
polysaccharide, and can in addition present the peptide part to T cells and receive the 
auxiliary signals [1].  
1.4.2 Vaccine longevity 
In general, vaccination gives a limited immune activation, and it is well conceived that the 
immune response after infection is impossible to achieve with vaccines without 
compromising with safety [20]. Amanna and Slifka have suggested that the plateau of 
induced Ab titers after a TI response is long-lived irrespective of the strength of induction. 
However, a weaker immune response produces fewer LLPCs, resulting in a lower and 
potentially not protective Ab level [105]. A booster vaccination with the same Ag will not 
only induce a short-term activation of MBCs, but also generate secondary GCs and increase 
the number of specific LLPCs [33], setting the Ab production to a higher level [20]. The key 
to an extensive LLPC pool is probably coupled to the quality of the preceding GC response, 
and the B-T cell interactions within it. By comparing vaccines with various capacity of 
generating long-term response, vaccine Ags have been classified into three types based on the 
strength of the T-B cell interaction (figure 1-4). The most efficient inducers of cell signaling 
are multivalent protein Ags, which will evoke ample BCR signaling and subsequent strong 
TFH signaling, in contrast to weaker response towards monovalent protein Ags. The third type 
used, multivalent Ags that only elicit a TI response, will not induce any long-term immunity 
[20]. 
Furthermore, one must not forget that Ab titers are not protective unless they target conserved 
and crucial parts of the pathogen, and exert a neutralizing action. These aspects have been 
some of the main obstacles in the development of a functional HIV vaccine [106].  
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Figure 1-4. Illustration of a putative model for B cell response and memory outcome after vaccination with 
multivalent or monovalent protein antigens, and a multivalent polysaccharide antigen, as suggested by Slifka 
and Amanna. Only protein antigens will lead to engagement of TFH cells, and multiple epitopes will increase 
the cell-cell interaction. A multivalent protein antigen is hence the most potent inducer of long-term 
immunity. 
Image source: [20]. Printed with permission from Elsevier. 
1.4.3 Measles and rubella vaccination 
Measles virus belongs to the Morbillivirus genus of the family Paramyxoviridae. It is 
highly contagious, spread by the respiratory route, and initially causing fever, coryza, 
cough, and conjunctivitis, where after a maculopapulous rash appears [107]. The most 
severe morbidity is caused by secondary infections due to measles-induced immune 
suppression [108], but the virus can also lead to the serious long-term complication 
subacute sclerosing panencephalitis (SSPE). The overall mortality of measles is around 5-
10 % in Africa, but can rise to 25 % without adequate health care [107, 108]. According to 
the World Health Organization, 145 700 deaths were caused worldwide by measles in 2013, 
mostly in low-income countries [109]. Though, the reported 2013 incidence in Europe was 
10 271 cases [110], proving that the disease still is a concern also in high-income countries. 
 
Rubella virus is the only known member of the Rubivirus genus of the Togaviridae family. 
It is spread through respiratory droplets, and causes a generally mild disease with fever, 
craniocervical lymphadenopathy and maculopapulous rash. Complications include 
encephalitis and arthritis, but are unusual and rarely fatal [111, 112]. However, infection of 
pregnant women has a high risk of causing congenital rubella syndrome (CRS), leading to 
severe malformations, including encephalopathy, microcephaly, hearing loss, cataracts, 
intrauterine growth retardation, and cardiac anomalies [111]. It is estimated that 110 000 
children are born with CRS yearly, making it the largest preventable cause of congenital 
defects worldwide [113]. 38 847 rubella cases were reported in Europe in 2013 [110]. 
 
Both measles and rubella are prevented by vaccination with live, attenuated viral strains, 
most commonly administered together with mumps virus in what is known as the MMR 
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vaccination. Its’ immunogenic potential is high, and it has an estimated protection rate of 
96-100 % in a healthy population after short-term evaluation (60-70 days) [112]. A long-
term evaluation in Finland 15 years after administration of a booster MMR dose showed 
that 95 % had measurable serum Abs against measles, and 85 % had titers above protection 
level. In the same cohort, 100 % had measurable Abs against rubella, and 93 % were above 
the protection level [114]. 
1.4.4 Tetanus vaccination 
Tetanus is caused by the gram-positive bacillus Clostridium Tetani, commonly through 
contamination of wounds with bacterial spores. The pathogenic effect is caused by the 
bacterial toxin, which enters the nervous system through the neuromuscular junction, and is 
transported to preganglionic inhibitory interneurons. Hampering of neurotransmitter release 
causes disinhibition of motor neuron discharge, leading to the characteristic skeletal muscle 
spasms [115, 116]. Mortality caused by airway compromise and later involvement of the 
autonomous nervous system is estimated to be 52 % in adults and up to 88 % in neonates, 
in areas with insufficient hospital care [116].   
 
Tetanus is a rare disease in Europe, with only 130 cases reported in total in 2010 [117]. The 
disease is mainly a challenge in neonatal and maternal care in low-income countries. 
Recent epidemiological data is scarce, but it is estimated that 49 000 infants died of tetanus 
in 2013 [118]. 
Vaccination against tetanus utilizes formaldehyde-inactivated toxin (toxoid) together with 
adjuvant, often administered together with inactivated diphtheria toxin and various 
preparations of subunits from Bordetella Pertussis. As is expected for subunit vaccines, Ab 
titers wane and a booster regimen is recommended to maintain protection [116, 119].  
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Table 1-3. The most recent version of the Swedish National Immunization Program, in use since 2009. Since 
January 1st 2010, a complementary decision recommends all girls to be vaccinated against Human 
Papillomavirus (HPV) at 10-12 years of age [120]. The table is a translation from publication number 2008-126-
9 from The National Board of Health and Welfare (Socialstyrelsen) in Sweden. Printed with permission from 
Socialstyrelsen.  
1.4.5 The Swedish National Immunization Program 
Vaccination guidelines for the Swedish population are published by The National Board of 
Health and Welfare (Socialstyrelsen). The current vaccine schedule used in Sweden was 
updated January 1st 2009 to the current regimen (table 1-3) [121]. Children born before 
2002 follow the earlier schedule (indicated in the table). Vaccine coverage is generally 
high, and it was estimated that > 95 % of all children in the 6th grade of school had received 
full vaccine protection against measles, rubella, mumps, diphtheria, tetanus, pertussis and 
polio in 2013 [122]. 
1.5 DISEASES AND PHARMACOLOGY TREATMENTS INTERFERING WITH B 
CELL MEMORY AND VACCINE EFFICACY 
The sophisticated series of events leading to B cell memory induction and preservation is 
vulnerable to interference from immune disorders and chronic infections. Moreover, non-
specific immunosuppressive treatment has the ability to ablate vaccine response, and as well  
disturb long-term preservation mechanisms. This section covers how selected diseases and 
treatment regimes affect vaccine-induced B cell memory.  
1.5.1 HIV-1 
Although the virus does not target B cells directly, a number of B cell malfunctions have been 
described in HIV-1 infected patients. Even before the connection was made between HIV-1 
and the development of Acquired Immunodeficiency Syndrome (AIDS), it was noted that B 
cells in AIDS patients seemed to be hyperactivated, leading to high levels of circulating Igs 
(hypergammaglobulinemia) [123]. Also other signs of B cell hyperactivation were later 
discovered, including increase of surface expression of activation markers, cell turnover, 
plasma blast differentiation, autoantibody production, and occurrence of B cell malignancies 
[59]. Despite the increased activation, individuals infected with HIV-1 have impaired 
induction and preservation of vaccine-evoked B cell memory [124], which is possible to 
Age 
Diphteria 
Tetanus 
Pertussis Polio 
Haemophilus 
Influenzae b 
Pneumo-
cocci 
Measles 
Mumps 
Rubella 
3 months I I I I 
 5 months II II II II 
 12 months III III III III 
 18 months 
    
I 
5-6 years IV** IV 
   6-8 years 
    
II** 
10 years IV* 
    12 years 
    
II* 
14-16 years V** 
    * Children born before 2002; **Children born 2002 and later	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partly restore by antiviral treatment [125]. As mentioned earlier (see chapter 1.3.4), the MBC 
compartment in HIV-1-infected individuals show an accumulation of unusual MBC 
phenotypes, probably due to exhaustion after constant immune activation [62, 126]. 
The reasons for the polyclonal hyperreactivity have been thoroughly investigated, but remain 
poorly understood. It has been shown that viral particles can act directly as polyclonal 
activators, that several B cell activation cytokines, such as BAFF and TNF-α, are increased in 
serum upon HIV-1 infection [59], and that there is an accumulation of TFH cells, suggested to 
drive constant activation of low-affinity Abs [127]. Probably, the overall pathogenesis is 
multifaceted.  
1.5.2 Cytotoxic therapy 
Chemical agents with cell toxic effects, defined as chemotherapy, generally affect cell 
proliferation. They are mainly used to treat malignant conditions by targeting rapidly 
proliferating cells, but can also be used in autoimmune disorders, such as rheumatic disease. 
These pathological conditions represent two distinct modes of treatment, in which the therapy 
is given either in a high dose for a limited time, or in a low dose for an extended time span, 
often without a set date of termination.  
1.5.2.1 Cytotoxic therapy in malignant diseases 
High-dose chemotherapy in cancer treatment commonly causes severe immunosuppression, 
by means of targeting proliferating hematopoietic cells in the BM, leading to decreased 
output of mature immune cells [128]. In addition, numerous studies of children going through 
treatment of acute lymphoblastic leukemia (ALL) have revealed that pre-existing vaccine-
induced circulating Abs can be lost after completion of treatment (reviewed in [129]). The 
same observation has been done in children after treatment for solid tumors [130], and in 
adult breast cancer patients [131]. The concomitant effects on specific vaccine-induced 
MBCs and LLPCs have not been investigated, but a general decrease of the MBC [132, 133] 
and BMPC [134] numbers has been observed. Moreover, children vaccinated during on-gong 
chemotherapy treatment have a decreased tendency to mount and/or sustain protective Ab 
titers [135]. Current recommendations suggest vaccination of children with relevant 
inactivated vaccines during chemotherapy, and re-vaccination of previously administered 
inactivated and live vaccines 3 months after treatment completion. The host potential to 
mount Ab titers shortly after treatment completion is considered adequate, but the supporting 
data is insecure, and more research is needed [136]. One aspect that is rarely studied is 
preservation of Abs for long-term, since most evaluations are done within months from the 
vaccination date. A study by Brodtman et al, examining 100 children that were re-vaccinated 
after treatment, revealed that several Ab titers were below protection level at follow-up after 
> 1 year [137]. Furthermore, it is not known if re-vaccination induces full recovery of the 
MBC compartment.  
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1.5.2.2 Cytotoxic therapy in rheumatic diseases 
The term rheumatic disease covers a variety of conditions, divided into four main groups: 
inflammatory joint diseases (for example rheumatoid arthritis), degenerative joint diseases 
(for example osteoarthritis or spondylitis), systemic rheumatic disease (for example SLE), 
and finally generalized pain syndromes [138]. A full description of the various diseases is 
beyond the scope of this thesis, and the focus will instead be on the treatment. 
The main cytotoxic agent used against rheumatic conditions is the replication inhibitor 
Methotrexate (MTX). As a folate analogue, it inhibits dihydrofolate reductase (DHFR) and 5-
amino-imidazole-4-carboxamide ribonucleotide (AICAR)-transformylase, both important for 
folate metabolism and subsequent construction of methionine, purine and thymidylate, which 
utterly leads to disrupted DNA synthesis [139]. As a side effect, accumulated AICAR inhibits 
adenosine deaminase, leading to increased levels of adenosine. The replication inhibitory 
consequences are utilized in cancer treatment, but the exact mechanisms behind its beneficial 
effects in rheumatic disease are not fully elucidated. Probably, a combination of reduced 
immune cell proliferation and increased concentration of anti-inflammatory adenosine is the 
dominating cause [139]. Additionally, a skewed T cell repertoire from inflammatory-related 
TNF-α to regulatory-related IL-10 producing cells has been observed [140].  
Both short- and long-term efficacy of vaccination in pediatric patients receiving MTX seem 
to be sufficient [141] [142], and MTX-treated adult rheumatoid arthritis-patients show 
preserved GC structure in tonsillar tissue [143]. Moreover, MTX does not seem to have any 
inhibiting effect on the total MBC frequency in adult [143] or pediatric patients [144]. 
However, MTX seems to hamper the BM output of newly formed transitional B cells [143, 
144], and there are some reports of a slightly decreased total B cell number [144, 145], in 
both adults and children. The long-term effects of suppressing the BM B cell output during 
development of the immune system in children are not known. 
1.5.3 Other antirheumatic drugs 
MTX belongs to the group of disease-modifying antirheumatic drugs (DMARDs), so named 
because of the ability to interfere with the disease process and influence its natural course. 
MTX is further classified as a synthetic DMARD (sDMARD), along with other chemical 
compounds, in contrast to the biological DMARDs (bDMARDs), that includes targeted 
monoclonal antibodies and soluble receptors [146]. Current treatment recommendations of 
Juvenile Idiopathic Arthritis, the rheumatic disease examined in this thesis, suggest initial 
start with sDMARDs, followed by bDMARDs in case of insufficient effect [147]. The 
bDMARDs that are most widely used are the TNF-α-inhibtors, a group that includes both a 
recombinant receptor analogue (etanercept), monoclonal Abs exerting an inhibitory effect on 
TNF-α binding (infliximab, adalimumab and golimumab), and a humanized IgG4 Fab 
fragment (certolizumab) with the same mechanism [148]. TNF-α is a cytokine with both pro-
inflammatory and immune regulating mechanisms, and has a prominent role in many 
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autoimmune disorders. Indeed, TNF-α-inhibition has shown a remarkable effect on various 
disease manifestations [148]. 
A number of studies have evaluated Ab responses to vaccination in paediatric rheumatology 
patients with TNF-α-inhibtors, and concluded that the short-term response (6-24 months) is 
adequate, but that long-term titre preservation (> 2 years) is insecure (reviewed in [141]). 
Furthermore, Anolik et al has found generally disrupted GC formation in adult rheumatoid 
arthritis-patients treated with etanercept, probably caused by cross-reactive inhibition of the 
GC-inducing cytokine TNF-β [143].  One knowledge gap is whether temporary intermission 
in treatment can boost the vaccine response. Clinical guidelines support this regime upon 
vaccination with live vaccines, due to the risk of inducing infection, but it has not been 
evaluated in any larger study [141]. In a study on 5 children with on-going anti-TNF-α 
treatment, no adverse events occurred when giving an MMR booster, and the Ab titers were 
adequate after 6 months [149]. However, more research is needed to draw relevant 
conclusions.  
The preservation of previously acquired vaccine-induced memory has not been selectively 
studied in the context of rheumatic treatment, and it is not known if full-vaccinated children 
are at risk of loosing protective Ab titers. 
1.5.4 Experimental studies on cytotoxic and bDMARD therapy on B cell 
memory  
Selectively pinpointing chemotherapy or bDMARD effects on B cell memory is connected 
with methodological difficulties in the clinical context. Firstly, both cancer and rheumatic 
patients display a range of disease-induced immunological abnormalities that possibly 
interfere with immunological memory [1, 150, 151], and secondly, adjuvant treatments are 
used concomitantly. Hence, experimental models are needed to conduct studies with a 
mechanistic approach. Vaccine response and GC formation has, to our knowledge, not been 
investigated in any animal model for antineoplastic or antirheumatic treatment, but the 
BMPC compartment has been addressed in a number of studies.  
One major feature of LLPCs is that they have exited the cell cycle and do not proliferate [45], 
putatively leading to chemotherapy resistance. In contrast, one aspect of chemotherapy-
induced BM toxicity that is rarely studied is the induced damage on the PC survival niche. As 
mentioned in chapter 1.3.9, both proliferating hematopoietic cells and resting BM stromal 
cells (CAR cells) act in concert to support PC survival [96], suggesting that different parts of 
the niche have various receptivity to cytotoxicity. It is not known if stromal cells can 
compensate for survival factors that are lost after depletion of hematopoietic cells. In 
addition, observations in BM transplanted humans indicate that also the BM stroma can be 
damaged by the excruciating pre-conditioning treatment, leading to impaired support for 
donor hematopoietic cell survival [152, 153]. Moreover, stromal cells from BM of pediatric 
ALL patients on maintenance chemotherapy showed reduced capability to support survival of 
developing hematopoietic cells in vitro [154], and experimental toxicology studies in murine 
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models and in vitro-cultured stromal cells have shown reduced survival and cytokine 
production after exposure to several different cytotoxic agents [155-157]. However, when 
interpreting this data, one needs to consider that terminally differentiated CAR cells have 
limited proliferative potential [96], and ex vivo cultures of BM stroma taken from patients 
probably consists of the precursors to CAR cells: mesenchymal stem cells [83]. If damage to 
mesenchymal cells with stem-cell properties has impact on the already established stromal 
niche is not known.  
The major contribution from the CAR cells in the PC survival niche is suggested to be the 
cytokine CXCL-12 [85, 158]. The CXCL-12/CXCR4 axis has been under thorough 
investigation in leukemia research, given its potential to attract leukemic stem cells that can 
cause relapse, and some specific inhibitors are in trial for therapeutic use [159]. Generalized 
DNA damage has been shown to induce increased levels of CXCL-12 in BM stroma [158, 
160], but also decreased production after MTX treatment has been observed [161]. The 
reason for conflicting data can be both time and dose dependent differences.  
1.6 SUMMARY 
Even today, vaccines belong to one the greatest achievements in the history of science. It is 
thus a fascinating thought that their mechanisms of action remained largely unrevealed for 
more than a century, and that we still lack fine and yet crucial pieces of the puzzle. It has 
been said that vaccinology has done more for immunology than vice versa, and this statement 
is largely true for our current knowledge about how B cells encounter Ags and form a 
functional immune memory. Taking off from the paradigm of a first line defense of 
circulating Abs, and a second line defense of MBCs, the aim of this thesis has been to join 
immunology and vaccinology together, and shed light upon some of the remaining 
unanswered questions. 
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2 AIMS OF THE THESIS 
The overall aims of this thesis are to elucidate how MBCs and LLPCs contribute to long-term 
vaccine-induced B cell memory: 
- In healthy children and young adults 
- In HIV infection and associated B cell deficiencies 
- Upon high-dose chemotherapy 
- Upon low-dose chemotherapy and TNF-α-inhibition   
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3 MATERIALS AND METHODS 
3.1 ISOLATION OF PERIPHERAL BLOOD AND BM MONONUCLEAR CELLS 
(ALL PAPERS AND PRELIMINARY DATA) 
In order to isolate mononuclear white blood cells from whole blood or BM, the high-density 
centrifugation technique was used. In brief, 15 ml of sodium chloride solution containing 
high molecular weight sucrose-polymers was poured into a 50 ml tube. The blood sample or 
BM aspirate was then carefully applied on top of the solution, and the tube centrifuged 
without brake for 20 minutes at 20.000 rotations per minute (RPM). The lightweight layer of 
mononuclear cells was then transferred to a new tube, using a pipette. The cells were washed 
once in Phosfate Buffer Solution (PBS) and once in Roswell Park Memorial Institute 
Medium (RPMI) before downstream assays. The RPMI used in all methods, if not otherwise 
stated, was of ATCC modification (including L-Glutamine, HEPES buffer, Sodium Pyruvate, 
and high glucose), and completed with 10 % fetal Calf Serum (FCS) and 1 % Penicillin-
Streptavidin-Fungizone solution. Washed peripheral blood mononuclear cells (PBMCs) or 
bone marrow mononuclear cells (BMMC) were thereafter cryopreserved in FCS with 10 % 
Dimethylsulphoxide at -150oC until further use. 
3.2 CHEMOTHERAPY TREATMENT (PAPER III AND PRELIMINARY DATA) 
As a model drug for experimental chemotherapy treatment, the replication inhibitor 
Doxorubicin was chosen. It belongs to the group of anthracyclins, and is widely used against 
numerous malignancies, including pediatric leukemias. The mechanisms leading to inhibition 
of cell proliferation remain a controversy, but involve intercalation directly to DNA, 
generation of free radicals and inhibition of Topoisomerase II [162, 163]. It can also induce 
apoptosis in non-dividing cells [164]. For paper III, the Doxorubicin dose was based on a 
pharmacokinetic study of the treatment analogue Daunorubicin, suggesting that a 60-minutes 
infusion of 30mg/m2 was tolerable for adult rhesus macaques [165]. For the preliminary in 
vitro model of BM stroma – PC interplay, the dose was based on pharmacokinetic data from 
children treated for ALL, showing plasma concentrations of 30-900 ng/ml [166].  
3.3 ENZYME-LINKED IMMUNOSORBENT ASSAY (ALL PAPERS AND 
PRELIMINARY DATA) 
For Enzyme-Linked Immunosorbent Assay (ELISA) a 96-well plate coated with Abs specific 
for the protein of interest was utilized. A serum sample or cell culture supernatant containing 
an unknown concentration of the protein was added to the wells, and incubated for an assay-
specific time. After removal of the solution, the wells were washed by filling and removal of 
PBS containing detergent (0.05 % Tween in the majority of assays used). A secondary Ab 
specific for the same protein was then added, targeting bound protein. The amount of bound 
secondary Ab was visualized with an enzymatic color reaction, most commonly using 
horseradish peroxidase, and the color change semi-quantified with an ELISA reader. The 
color in each well was related to a standard curve with known concentration. To quantify 
specific Abs in serum, the plates were instead of Abs coated with the selected Ag, and the 
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secondary Ab was directed towards the immunoglobulin type if interest. In the included 
papers herein, only IgG was detected.   
3.4 TEST OF ANTIBODY AVIDITY (PAPER IV) 
The overall binding capacity of specific Abs (avidity) was estimated with an Ag-coated 
ELISA plate, to which the serum of interest was added. Incubation of Urea solution in the 
first wash step allowed removal of low-avidity Abs, and comparison with wells treated with 
only PBS gave an estimation of the overall avidity. The data are expressed as proportional 
color intensity in Urea wells compared to the control wells.  
3.5 POLYCLONAL ACTIVATION OF MBCS AND DIFFERENTIATION TO AB-
SECRETING CELLS (PAPERS II, III AND IV) 
The functionality and specificity of the MBCs in PBMC samples was determined by 
differentiation to Ab-secreting cells in vitro. In brief, the cells were incubated for 72 hours in 
RPMI containing activation signals for innate receptors of B cells, inducing a polyclonal 
activation that lead to differentiation into short-lived plasma blasts. The protocols used in 
paper II are given in detail within the paper. The protocol used in papers III and IV is given in 
detail in paper IV. BMMCs in paper III were used for ELISpot without prior activation. As 
BM samples from two Doxorubicin-treated rhesus macaques in paper III contained 
overwhelming amounts of maturing hematopoietic cells on study day 73, these samples were 
enriched for CD38+ cells with a magnetic bead-based method, according to manufacturer’s 
instructions, before ELISpot assay. 
3.6 ENZYME-LINKED IMMUNOSPOT ASSAY (PAPERS II, III AND IV) 
The Enzyme-Linked ImmunoSpot (ELISpot) assay is similar to Ag-directed ELISA, but 
utilizing Ab-secreting cells instead of serum. Briefly, pre-wetted membrane plates were 
coated with the Ag of interest, after which PBMCs or BMMCs were added, and the Abs 
produced attached in clusters. After removal of the cells, the bound antibodies were 
visualized with an enzymatic color reaction, creating dark spots at the locations of each Ab-
secreting cell. The number of spots was then used to estimate the number of specific Ab-
secreting cells per added PBMC, which was related to the total number of IgG-secreting cells 
in the same sample, determined by using wells coated with anti-IgG Abs. The detailed 
protocol used in paper II is given in the paper. The detailed PBMC protocol used in papers III 
and IV is given in paper IV. The protocol for BMMC ELISpot in paper III was the same as 
for PBMC, but the plates were incubated for 6 hours instead of 16-24 hours. 
3.7 FLOW CYTOMETRY (ALL PAPERS AND PRELIMINARY DATA) 
Flow cytometry is a technique that, in a suspension of cells, enables quantitative evaluation of 
single cell characteristics based on light scattering and fluorescence. This is accomplished by 
a high flow in the cytometer that creates a single-cell stream of cells that pass laser beams. 
The size of each cell is estimated by means of how the light is scattered before quantification 
by a front filter (forward scatter), whereas the light scatter on a side filter (side scatter) is a 
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measure of cell granularity. In addition, the laser induces excitation of fluorescent parts on the 
cells, and the emitted light is captured and measured. By labeling specific proteins on the cell 
surface with Abs conjugated to fluorescent molecules, information about several markers of 
interest can be detected on each cell. The Abs used in this thesis were all monoclonal, and the 
names of the specific clones are given in each paper.     
3.8 QUANTITATIVE POLYMERASE CHAIN REACTION (PAPER I) 
Polymerase Chain Reaction (PCR) utilizes a DNA polymerase and complementary primer 
DNA sequences to multiply copies of a DNA fragment of interest. In paper I, complementary 
DNA was coded from extracted cell-produced RNA. The amount of DNA produced in the 
reaction was measured with fluorescent probes, and related to the production of the β-actin 
gene, known to be stably expressed regardless of treatment. The data are presented as fold-
change of gene expression compared to non-treated cells. A detailed protocol is given in 
paper I. 
3.9 IN VITRO CO-CULTURE ASSAY (PRELIMINARY DATA) 
In order to study the interplay between the BM stromal cells and LLPCs in further detail, an 
in vitro co-culture assay was developed.  
3.9.1 Cell line model for the stromal cell niche 
As a model for BM CAR cells, the human BM-derived stromal cell line HS-27 was used, due 
to its known expression of VCAM-1 and CXCL-12 [167, 168]. Analysis of HS-27 in our lab 
also demonstrated significant production of IL-6. The cells were kept in culture flasks at 37oC 
in 5 % CO2, and fed every 2-3 days with RPMI. For the experiments, the cells were seeded in 
24-well plates and grown to monolayers for 48 hours. The monolayers were exposed to 
Doxorubicin, diluted in RPMI to a concentration of 1 µg/ml, for 60 minutes, after which they 
were washed 3 times with RPMI. Control wells were exposed to RPMI without Doxorubicin, 
with the same number of medium changes. The procedure was repeated for 5 consecutive 
days.  
3.9.2 Differentiation of PCs from MBCs in vitro 
Differentiation of MBCs to LLPCs was performed according to the protocol developed by 
Jourdan et al [169]. In brief, CD27+ B cells were separated from PBMC from healthy blood 
donors, using a commercial magnetic bead separation assay. The MBCs were cultured in 6-
well plates at a concentration of 1.5x105 cells/ml in Iscoves modified Dulbecco medium 
(IMDM) supplemented with Penicillin-Streptomycin-Fungiszone, 10 % fetal bovine serum, 
50µg/ml human transferrin and 5 µg/ml insulin. The medium was completed with 
recombinant CpG, TNF-α, IL-2, IL-6, IL-10 and IL-15 in different combinations for 10 days 
in total (table 4-2). Analysis with flow cytometry (see chapter 3.9.3) showed that between 30 
and 50 % of the added cells completely lost expression of CD20, acquired the specific plasma 
cell marker CD138 and were hence classified as terminally differentiated plasma cells (figure 
4-4, A). The CD138+ fraction was thereafter separated in a magnetic bead assay, and 
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dissolved in complete IMDM without additional recombinant cytokines.  
3.9.3 Co-culture of PCs and stromal cells 
After the last Doxorubicin exposure, the RPMI was carefully discarded from the stromal cell 
layers, and the separated PC fraction was added at a concentration of 3x105 cells/ml. The co-
cultures were incubated for 7 days without medium change. At harvest, the culture 
supernatants were frozen at -20oC, and the cells taken for flow cytometry analysis using a cell 
scraper. The cells were stained according to standard procedures with fluorescence-
conjugated Abs against the following proteins (specific clones in brackets): CD38 (HIT2), 
CXCR4 (12G5), CD20 (L27) and CD138 (MI15). A fixable dead cell marker was used to 
exclude non-viable cells from the analysis, and a known number of fluorescent beads was 
added to each tube to estimate cell numbers. The supernatants were later analysed with 
ELISA to measure the concentrations of soluble IL-6, CXCL-12 and IgG. 
Culture day 0 4 7 10 
 
Added to 
medium 
 
CpG (10 µg/ml) 
CD40L (50 ng/ml) 
anti-polyhistidine (5 µg/ml) 
IL-2 (100 ng/ml) 
IL-10 (50 ng/ml) 
IL-15 (10 ng/ml) 
IL-2 (100 ng/ml) 
IL-10 (50 ng/ml) 
IL-6 (50ng/ml) 
IL-15 (10 ng/ml) 
IFN-α (500 U/mL) 
IL-6 (50ng/ml)  
IL-15 (10 ng/ml) 
Co-culture 
with HS-27, 
no added 
cytokines 
Table 4-2. Protocol for in vitro activation and plasma cell (PC) differentiation of separated primary CD27+ 
memory B cells. For all steps, the cells were kept in 6 well-plates at a concentration of 1.5x105 cells/ml in 
Iscoves modified Dulbecco medium (IMDM), supplemented with Penicillin-Streptomycin-Fungizone, 10 % 
fetal bovine serum, 50µg/ml human transferrin and 5 µg/ml insulin. The cells were washed in Phosfate Buffered 
Saline between medium changes. On culture day 10, the PC fraction was separated with magnetic beads 
targeting CD138, and added onto HS-27 cultures in IMDM without cytokines.   
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4 RESULTS 
4.1 PRESERVATION OF VACCINE-INDUCED MBCS 
We evaluated the survival of vaccine-induced MBCs in healthy children and young adults 
(paper II) and upon two distinct types of immunomodulatory treatment (papers III and IV).  
In healthy children who had followed the Swedish National Immunization Schedule, we 
showed that the first vaccine dose against measles and rubella induced adequate numbers of 
functional specific MBCs, which did not vanish with time and were preserved up to 9 years 
after vaccination (figure 4-1, A-B). Also, in healthy young adults who had received a second 
vaccine dose, specific MBCs were measured up to 18 years after vaccination with no sign of 
decay. The general MBC compartment, quantified with flow cytometry, did not change with 
age in our cohort.  
Figure 4-1. Healthy children who had received one dose measles and rubella vaccine were sampled 1-10 years 
after vaccination. Memory B cells specific against measles (A) and rubella (B) did not follow a trend of decrease 
with time, whereas serum measles (C) and rubella (D) IgG titers were markedly lower longer time after 
vaccination. 
Next, we wanted to evaluate the survival of vaccine-induced MBCs upon chemotherapy 
treatment in a rhesus macaque model. Healthy measles-vaccinated rhesus macaques were 
given 3 infusions of Doxorubicin, at doses that were estimated to induce BM toxicity, or 
saline solution (5 animals were used in each group). 28 days after the last dose, all animals 
were re-vaccinated against measles and de novo vaccinated against rubella and tetanus (table 
4-1). Flow cytometry and ELISpot quantification of the B cell compartment showed that both 
general and measles-specific resting MBCs were almost completely diminished 15 days after 
the last Doxorubicin dose (figure 4-2, A-B). Consecutive sampling showed adequate 
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recovery, and the MBC levels were comparable between the groups 43 days after cessation of 
treatment. 
Table 4-1. Overview of handling and sampling of the rhesus macaques used in paper III. In addition to the 
outlined sampling, frequent peripheral blood samples were taken for measurement of clinical chemistry 
parameters, and cryopreservation of serum. Furthermore, consecutive bone marrow biopsies and whole lymph 
nodes were taken for cryopreservation (not used for this thesis work). The treatment group (n = 5) received the 
Doxorubicin doses intravenously for 1 hour. The control group (n = 5) received saline solution under equal 
circumstances. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2. Evaluation by flow cytometry and ELISpot of pre-existing B cell memory in Doxorubicin treated 
and control rhesus macaques. Memory B cells (MBCs) were defined as viable CD19+ CD27+ single 
lymphocytes, and plasma cells (PCs) as viable CD19+, CD20+/-, CD38Hi, CD138+ single bone marrow (BM) 
cells. All data show a comparison before treatment (day 0) and 15 days after the last Doxorubicin dose (day 73). 
Horizontal lines signify median levels in each group. Both the general (A) and measles-specific (B) MBC 
compartments were severely decreased in the treated compared to the control group on day 73 (p < 0.05). Also 
the amount of functional IgG+ MBCs was almost completely eradicated at the same time point (C, p < 0.01). In 
contrast, the general (D) and measles-specific (E) BMPC frequencies did not differ between the groups. The 
findings are further demonstrated with representative ELISpot wells from study day 73 (F). 
 
After examining high-dose short-term treatment, we wanted to evaluate whether low-dose 
long-term chemotherapy would have the same consequence. We thus returned to evaluate 
Study day 0 14 28 58 73 86 101 121 136 175 211 
 
Handling Doxorubicin 
30 mg/m2 
 
Doxorubicin 
50 mg/m2 
Doxorubicin 
75 mg/m2 
 
 
MMR + tetanus 
vaccination 
    
Euthanasia 
      
Sampling BMMCs 
PBMCs 
BMMCs  
PBMCs 
  
BMMCs  
PBMCs 
 
BMMCs  
PBMCs PBMCs PBMCs PBMCs 
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PBMCs 
BMMCs = bone marrow mononuclear cells, PBMCs = peripheral blood mononuclear cells 
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immunity in children who had followed the Swedish National Immunization Schedule, but 
now compared healthy children to patients treated with the cytotoxic drug methotrexate 
(MTX) against rheumatic disease, in a cross-sectional study. We furthermore asked if 
additional treatment with TNF-α-inhibiting drugs would add to an effect, and included 
children from three groups: healthy controls, rheumatic patients with only MTX, and 
rheumatic patients with both MTX and one TNF-α-inhibitor. Flow cytometry analysis 
showed that the number of transitional B cells was decreased in the rheumatic patients, but 
that the MBC compartment was similar between all groups (figure 4-3, A-B). ELISpot 
analysis demonstrated that children that had received two doses of measles and rubella 
vaccine, and four doses of tetanus vaccine, had comparable levels of MBCs specific against 
measles, tetanus and rubella, irrespective of treatment. In contrast, rheumatic patients who 
had only received one dose of measles vaccine had significantly lower frequencies of 
measles-specific MBCs (figure 4-3, C).  
Figure 4-3. Peripheral blood mononuclear cells (PBMCs) from children with rheumatic disease and treatment 
(RD), and age-matched healthy controls (HC), were analyzed with flow cytometry and ELISpot. Total B cells 
were defined as CD19+ CD14- viable lymphocytes, mature B cells as CD10- B cells, transitional B cells as 
CD10+ CD21+ CD38+ B cells, naïve B cells as CD27- CD21+ mature B cells, resting memory B cells (MBCs) 
as CD27+ CD21+ mature B cells, activated MBCs as CD27+ CD21- mature B cells and atypical MBCs as 
CD27- CD21- mature B cells. The frequencies of transitional B cells of all CD19+ cells were decreased in 
children with rheumatic disease (A), whereas the distribution of cell populations within the mature B cell 
compartment did not differ significantly (B). In patients with only basic measles and rubella protection (1 MMR 
dose), the frequencies of measles-specific MBCs were significantly lower than in the controls (C). 
4.2 FUNCTION OF MBCS IN DISEASE AND TREATMENT MODELS 
The overall functionality of the MBC pool in the rhesus macaque model (paper III) and in 
children treated with anti-rheumatic treatment (paper IV) was evaluated by the ability to 
produce IgG upon polyclonal activation. In line with the flow cytometry quantified MBC 
frequencies, the amount of functional IgG-producing MBCs was severely diminished in the 
rhesus macaques 15 days after the last Doxorubicin dose (figure 4-2, C). Also coherent with 
flow cytometry data, children with and without antirheumatic treatment had similar 
frequencies of IgG producing MBCs after polyclonal activation. In both treatment models, 
the number of ELISpot-quantified functional IgG-producing MBCs correlated strongly to the 
flow-cytometry quantified frequencies of resting MBCs (p < 0.0001 for both studies). 
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In the rhesus macaque model, induction of a B cell response after vaccination shortly after 
cessation of chemotherapy treatment was also evaluated. We found that both rubella- and 
tetanus-specific MBCs were formed to the same extent as in the control group, but somewhat 
delayed, as the amounts were significantly lower 15 days after vaccination. Short-term 
evaluation of specific serum IgG, an indicator of a productive initial immune response and 
GC reaction, showed the same pattern. Moreover, 4 months after de novo or booster 
vaccination, both measles- and rubella-specific BMPC frequencies correlated positively to the 
corresponding specific serum IgG, irrespective of treatment (p = 0.014 for measles and p = 
0.0046 for rubella). 
In HIV-1 infected individuals, we investigated an alternative pathway for MBC activation, 
and its putative role in hyperactivation of MBCs that is seen in these patients (paper I). We 
could show that recombinant CD27 induced a dose-dependent IgG production in MBCs in 
vitro without BCR stimulation, exerted by the ligation of CD70 on B cells. Furthermore, 
incubation with sCD27 induced expression of the PC differentiation transcription factors 
Blimp-1 and XBP-1. MBCs from HIV-1 infected patients expressed elevated levels of CD70 
compared to the healthy donors, and the IgG-producing effect of sCD27 stimulation was also 
more pronounced. Finally, we analyzed the patients’ serum levels of IgG and CD27, and 
confirmed that they were higher than in healthy controls. Serum IgG correlated to sCD27 
levels in both HIV-1 infected and healthy individuals, suggesting a role for the CD27-CD70 
pathway of MBC activation in humans, potentially more active during HIV-1 infection.  
4.3 PRESERVATION OF VACCINE-INDUCED LLPCS 
We measured specific serum IgG as a secondary measure of LLPC number and function in 
healthy individuals (paper II) and upon two distinct types of immunomodulatory treatment 
(papers III and IV). In the rhesus macaque model for antineoplastic treatment, we were also 
able to quantify the number of total and Ag-specific BMPCs (paper III). In addition, we 
studied the details of how chemotherapy can interfere with PC survival in an in vitro model 
of the BM stromal cell niche (preliminary data). 
In healthy children sampled 1-9 years after vaccination, we noted that specific IgG induced 
after one measles and rubella vaccine dose decreased with time, in contrast to the stable 
population of MBCs (figure 4-1, C-D). Out of the children with low Ab titers, > 50 % had 
high levels of MBCs. In contrast, in young adults who had received two vaccine doses, 
sampled at least 7 years after the last dose, the specific IgG titers showed no sign of time-
related decay. 
In the Doxorubicin-treated rhesus macaques, Abs against measles turned out to be stably 
preserved, and neither was the total and specific BMPC compartment affected (figure 4-2, D-
E). This contrasted markedly against the loss of specific MBCs in the same animals. 
Likewise, in rheumatic children treated with low-dose MTX for long term, both measles- and 
rubella-specific serum IgG titers were similar to age-matched controls, irrespective of 
concomitant TNF-α-inhibitory treatment. Tetanus-specific serum IgG was however decreased 
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in the rheumatic patients compared to the controls both for individuals with basic (p = 0.029) 
and full (p = 0.031) tetanus vaccine protection.  
We next sought to map the effects of Doxorubicin on the stromal cell – PC interplay in more 
detail, using an in vitro model. We discovered that repeated exposure to in vivo relevant 
concentrations of Doxorubicin could hamper the production of CXCL-12 and IL-6 from the 
stromal cell line HS-27 (figure 4-4, B-C). Accordingly, the surface expression of CXCR4 on 
co-cultured PCs increased (figure 4-4, D). Even though the number of surviving PCs 
correlated to the concentration of IL-6 and CXCL-12 in the cultures (figure 4-4, E-F), 
Doxorubicin-exposure decreased neither PC number nor IgG production (figure 4-4, G-H). 
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Figure 4-4. In vitro derived plasma cells (PCs) were kept for 7 days on the cell line HS-27, as a model for cross 
talk between PCs and CXCL-12-abundant reticular cells (CAR cells). Half of the wells with monolayers of HS-
27 were exposed to Doxorubicin (Dx) 1 hour per day for 5 consecutive days, before addition of PCs. (A) 
representative FACS plot after completed PC differentiation. The CD138 fraction was purified with magnetic 
bead separation before addition onto the HS-27 monolayer. B-H: evaluation of co-cultured PCs with flow 
cytometry, and corresponding supernatants with ELISA. The concentrations of CXCL-12 (B) and IL-6 (C) in the 
co-cultures were significantly lower in Dx-exposed wells. The PC median fluorescence intensity (MFI) of 
CXCR4, the natural receptor for CXCL-12, was negatively correlated to the concentration of CXCL-12 in the 
supernatants (D). The number of CD138+ cells after 7 days of co-culture correlated to the supernatant 
concentrations of IL-6 (E) and CXCL-12 (F). Though, when comparing control wells with Dx exposed, the 
number of CD138+ cells (G) and the produced IgG (H) did not differ significantly. Data are from 3 independent 
experiments, using 6 healthy blood donors in total.  
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5 DISCUSSION 
5.1 THE SURVIVAL AND FUNCTION OF LLPCS 
The idea of a population of LLPCs resident in the BM, responsible for continuous Ab 
production, was first proposed by Rudolph Manz and colleagues in 1997 [170]. Since then, 
numerous experimental and observational studies have supported this hypothesis 
(summarized in chapter 1.3.8), but there are still some fundamental questions that remain to 
be answered.  
5.1.1 Establishment of LLPCs 
Firstly, when does the production of Igs shift from newly formed plasma blasts and SLPCs to 
the LLPC population? When evaluating IgG titers in humans, longitudinal data imply that the 
host reaches is a steady state when there is hardly any decay of a number of specific Abs 
[105], suggested as the time when the production has shifted completely to LLPCs. However, 
it seems to take 1-3 years before that occurs [42, 171]. It is not known if Abs produced before 
the steady state are from newly formed SLPCs, or if the number of LLPCs decay in the 
beginning or their establishment. Previously considered to be a relatively short-lived event, 
there is now evidence that a GC reaction can last for months after Ag encounter [33], 
implying that at least part of the initial Ab kinetics is due to slowly diminishing of the SLPC 
production. Perhaps, the “intermediate phase” of the Ab response is due to a combination of 
formation of new SLPCs, and LLPCs competing for their place in the BM niche (figure 5-2).  
The notion that Ab titers are not stable until years after vaccination raises the question if titer 
quantification earlier does not represent the true long-term response. This finding was 
mirrored in paper II, where we concluded that there was a strong correlation between Ab titer 
and time since vaccination during the first years. Since sampling limitations in human 
patients hinder investigation of establishment of LLPCs in the BM, we utilized a rhesus 
macaque model for this investigation (paper III). We lack measurements later than 4 months 
after vaccination, but we nevertheless noticed that specific IgG correlated to the number of 
specific BMPCs at our latest measured time point. Furthermore, another vaccination study in 
cynomolgus macaques concluded that the serum IgG was mainly resulting from BM 
production 29 weeks after vaccination [172]. These findings contradict the model outlined 
above, but we cannot know, however, if the Ab-secreting population that was measured in the 
BM was genuinely long-lived, or consisted of recent arrivers yet to be incorporated in the 
niche. One suggestion is that the BM not only is a home for LLPCs, but also a short-term 
residence for cells with a limited life span. Possibly, there is a need to introduce the existence 
of a “middle-aged” PC, to explain the pattern that is observed the first years after Ag 
encounter. 
5.1.2 Regulation of the BM niche and longevity of the Ab protection 
There have been many suggestions on how the influx of new BMPCs is regulated. Given that 
the BM niche is spatially limited, how can the continuous encounter of new pathogens 
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generate PCs for a lifetime? The most recognized hypothesis is that there is an on-going 
competition for space, leading to an expulsion of resident PCs upon new PC formation. This 
would lead to a gradual decrease of Ab production with time, however sufficient for lifetime 
protection [173]. One observation supporting this hypothesis is the occurrence of multi-
specific PCs in peripheral blood after vaccination [174]. What remains to be explained, 
though, is why some Ab titers show no sign of decay at all, whereas others have a relatively 
short half-life [105]. One proposal is that the fate of the PC is decided already in the GC 
reaction, where multivalent Ags engage strong T cell help and mount more LLPCs (see 
chapter 1.4.2). This hypothesis is strengthened by recent data on how LLPCs are formed in 
the GC, favoring a selection of the B cells with highest affinity and hence generated after 
strong signals from the BCR and T cells (see chapter 1.3.2). This would mean that some Ag 
responses are “destined” to wane from the beginning (applicable to both tetanus and pertussis 
responses, both generated from monovalent Ags) giving space for PCs generated after 
stronger stimulation [42]. One must however bear in mind that the Abs probably do not reach 
zero level, even if we do not detect them [20]. In other words, immunity to monovalent Ags 
can still be bona fide long-lived, but generated by too few LLPCs to be protective (figure 5-2, 
B) 
5.1.3 Implications for patients with immunosuppressive treatment 
Chemotherapy and TNF-α-inhibitory treatment hypothetically interferes negatively with 
mounting and preservation of a vaccine response (outlined in chapter 1.5 and summarized in 
figure 5-1), but the consensuses regarding treated children suggest that both groups have 
protective Ab response after vaccination [136]. However, assuming that the long-term 
preservation of Abs should be evaluated at least 1-3 years after vaccination, perhaps one 
needs to re-consider these conclusions. We found clearly lowered titers against tetanus in 
children after long-term follow up (paper IV) and coherently, two studies done on long-term 
assessment (> 1 year for children with cancer and  > 2 years for children with rheumatic 
diseases) found lower Ab titers in both groups, compared to healthy controls [137, 142]. 
Could this be due to an inferior GC response with too few generated LLPCs, which will not 
be noted as long as the titer evaluation is done within the intermediate phase of Ab 
production (figure 5-2, C)? In paper IV, we concluded that tetanus titers in rheumatic patients 
were of the same avidity as in the healthy controls, thus probably generated from GC 
reactions and not from extrafollicular responses. However, many of the children had their 
diagnosis before booster vaccination, and it cannot be excluded that immune suppression 
caused by both the disease and the treatment, can have interfered with the number of LLPCs 
generated. The same can possibly be valid after antineoplastic treatment and subsequent 
vaccination. It is, for example, not evaluated when FDCs can re-establish and operate 
functionally after high-dose chemotherapy. We showed in our in vitro model that BM stromal 
cells decrease CXCL-12 production after Doxorubicin treatment (preliminary data), and a 
similar disturbed secretion of CXCL-12 or CXCL-13 in a GC would have devastating effects 
on its architecture and function. Furthermore, the broad nature of a general cytotoxic effect 
might also impair delicate functions of the main GC players, such as presentation of Ag by B 
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cells or FDCs, or expression of CD40L by TFH cells. The selective decrease of tetanus titers 
could be explained by the already mentioned limitation of the Ag in itself, and thus an 
increased vulnerability to additional stress. 
In addition to a suboptimal GC reaction, chemotherapy might disrupt the function of the BM 
niche, which we hypothesize causes the loss of pre-existing Abs after antineoplastic treatment 
(outlined in chapter 1.5.4 and summarized in figure 5-1). It is largely unknown how the niche 
is regenerated after an insult, or if the non-proliferating CAR cells at some point succumb to 
treatment and are replaced by maturation of mesenchymal stem cells, or – on the contrary – if 
surviving CAR cells exhibit a suboptimal function. As mentioned above, data from our in 
vitro model demonstrated that CAR cell production of the survival factors CXCL-12 and IL-6 
was inhibited after Doxorubicin exposure, but if renewal of the hematopoietic part of the 
niche can compensate for this deficiency is hard to predict. Knowledge about the niche 
function after cytotoxic treatment would be an important clue to development of effective re-
vaccination schedules after completed cancer treatment regimes.  
Furthermore, children are at higher risk than adults to acquire side effects from proliferation 
inhibitory treatment. For example, their high bone remodeling rate, induced by mesenchymal 
stem cell activity, leads to increased sensitivity to bone cancer after irradiation therapy [175]. 
It can hence be speculated that cytotoxic treatment in children is able to affect other functions 
of mesenchymal stem cells, such as establishment of the spatial diversity of BM niches. 
Nevertheless, long-term effects after antineoplastic treatment on BM constitution, or 
specifically the LLPC niche, are largely unstudied. Finally, one must not completely rule out 
the possibility of chemotherapy interference directly with the PC intracellular machinery, for 
example proteasome activity, known to induce PC apoptosis [176]. 
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Figure 5-1. Summary of the elicited hypotheses on how chemotherapy and TNF-α-inhibitory treatment might 
interfere with long-lived plasma cell (LLPC) production and long-term maintenance. TNF-β inhibition most 
likely occurs only upon TNF-α-inhibitory treatment. FDC = follicular dendritic cell, TFH = follicular helper T 
cell, GC = germinal center, CAR cell = CXCL-12-abundant reticular cell. 
5.2 SALVAGE BY MBCS? 
One of the main aims of this work has been to compare the contribution of LLPCs and MBCs 
to long-term immunity, and their relative susceptibility to immunosuppressive treatment. We 
concluded in paper II that healthy children can mount an adequate number of MBCs despite 
low IgG titers, and that MBC levels are stable before a steady state of Ab production. 
Somewhat contradictory, we saw in paper III that MBCs vanished after high-dose short-term 
chemotherapy treatment, whereas Ab titers were preserved, but the opposite was shown in 
paper IV after low-dose long-term treatment. Maintenance of MBCs is mechanistically not 
well mapped, and it is not known whether intrinsic or extrinsic signals play the most crucial 
role. However, their proliferating nature stipulates a general vulnerability for replication 
inhibitory drugs, and their resistance to MTX is surprising. This indicates that there is 
influence of other, protective signals that outweigh the cytotoxicity, possibly provided by 
surrounding cells. Assumingly, these signals are not enough to prevent cell death in the case 
of a higher chemotherapy dose. 
How MBCs circulate between peripheral blood and various lymphoid organs is not fully 
understood, and we do not know if the evaluated MBCs from blood samples are truly 
representative. Perhaps the fast recovery of measles-specific MBCs that we noted in the 
rhesus macaque model in paper III can be explained by a preserved population in another 
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anatomical site, either not reached by the same drug concentrations as in peripheral blood, or 
equipped with more survival factors.  
The most intriguing question is though which protective role the MBC compartment plays in 
the case of antigenic challenge, currently not known as studies on vaccine efficacy have thus 
far only evaluated Ab titers in terms of protection. One clue has come from studies of the 
Hepatitis B vaccine, known to induce serum IgG only for a limited time, but to provide 
protection despite titer waning. To test the protection capacity of Hepatitis B-specific MBCs, 
re-vaccination was used as a model for Ag re-challenge in one study on vaccinated children 
[177]. Indeed, children with similar MBC levels responded equally well to re-vaccination, 
regardless of IgG titer levels. If this conclusion is valid, also after infectious antigenic 
challenge, is however hard to predict. 
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Figure 5-2. Hypothetical illustration of how the antibody (Ab) response might appear after a single vaccine 
dose. During the early phase, Ab production is only due to short-lived plasma cells (SLPCs, dashed line), 
whereas the long-lived plasma cells (LLPCs, whole line) appear later, and peak after 4-5 weeks. The Ab 
production in the intermediate phase comes both from a prolonged GC response, giving rise to new SLPCs, and 
LLPCs competing for space in the bone marrow (BM) niche. There is thus a decline of Abs throughout the 
intermediate phase, which hypothetically last for years according to longitudinal human data. The late phase is 
initiated as the SLPC response is over, and the number of LLPCs is fixed in the BM, leading to a life-long steady 
state. In the case of a multivalent Ag (A), the number of LLPCs is high enough to produce Abs above the 
protection level, whereas a monovalent Ag (B) gives rise to fewer LLPCs, setting the steady state Ab production 
at a lower, non-protective, level. Upon antineoplastic or antirheumatic treatment (C), the number of LLPCs is 
reduced due to the interference with the GC response summarized in figure 5-1, and in addition, the long-term 
maintenance in the BM is impaired. The late phase of Ab production is thus both lower from the beginning, and 
not kept in a steady state. The illustration is inspired by findings from the studies included in this thesis, and 
from observations reported by Amanna and Slifka [20, 42]. 
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5.3 FUTURE DIRECTIONS 
The long-term goal with our studies is to find clues to better vaccine protection of children 
with treatment against cancer and inflammatory diseases, but several challenges remain in 
this strive. Most importantly, preservation of vaccine-induced immune cells must act in 
concert with elimination of pathological cells. In hematological malignancies, directed 
therapy towards the BM niche has become of importance as this compartment has turned out 
to act as shelter for surviving malignant cells [178]. Similarly, treating autoreactive LLPCs 
has emerged as an important tool to treat refractory autoimmune disease [179]. This 
emphasizes the need for more targeted therapy, for example emerging immunotherapy in 
malignancies [180], enabling lower doses of broadly toxic drugs. For autoimmune disorders, 
a new application of the affinity matrix technology has recently demonstrated the potential of 
killing BMPCs based on antibody specificity, opening up for elimination of solely 
autoantibody producing PCs [181].  
Mechanistic studies of the BM niche is coupled to many challenges, as the PC-preserving 
part is estimated to be an extremely small fraction of the entire BM [83], and cultured cells of 
mesenchymal origin are prone to change their original expression of surface molecules [182]. 
In vitro models are nevertheless needed to generate new hypotheses and look into 
mechanistic details, complemented by evolving in vivo imaging techniques [96], and utterly, 
studies on sectioned human BM biopsies.  
In addition to BM-directed research, we need to further outline the protective capacity of the 
MBC compartment, to understand if the second line of B cell defense can compensate when 
the first line is impaired. We hence need better methods to study both MBC maintenance and 
their role in antigenic re-challenge, emphasizing the need for studies on human SLOs. 
Likewise, more interest should be aimed at direct effects on SLO structure and function upon 
generalized immunosuppressive treatment, and how this potentially hamper of vaccine 
efficacy.  
To summarize, the optimization of vaccine protection in patients with immunosuppressive 
treatment is an area where vaccinology is in great need of basic immunology research, and it 
cannot be done without using both pre-clinical and translational approaches. Hopefully, our 
contribution is a small step on the road.  
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